ValuEngine upgraded shares of Bioamber (NYSE:BIOA) from a sell rating to a hold rating in a report issued on Wednesday.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Bioamber from a sell rating to a hold rating in a report on Tuesday, January 9th. HC Wainwright restated a buy rating and set a $12.00 price target on shares of Bioamber in a report on Wednesday, November 8th. Finally, Cowen restated a hold rating and set a $1.00 price target on shares of Bioamber in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $6.50.
Bioamber (BIOA) opened at $0.07 on Wednesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.75 and a current ratio of 1.08. Bioamber has a fifty-two week low of $0.05 and a fifty-two week high of $3.74. The company has a market cap of $1.21, a price-to-earnings ratio of -0.10 and a beta of 2.52.
Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 41,701 shares in the last quarter. Robecosam AG boosted its holdings in Bioamber by 82.9% in the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 670,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Bioamber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 27,278 shares in the last quarter. Finally, FMR LLC boosted its holdings in Bioamber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Bioamber (BIOA) Raised to Hold at ValuEngine” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/17/bioamber-bioa-raised-to-hold-at-valuengine.html.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.